法国ICU脑损伤患者镇静镇痛一日前瞻性全国观察研究:SEDA-BIP-ICU研究
该研究分两部分:对30个法国ICU(27个学术医院)的镇静实践进行描述性调查,并对全部脑损伤患者进行一日前瞻性横断面快照。研究日共246例脑损伤患者,74例(30%)接受镇静,其中53%因颅内高压、19%因躁动谵妄、9%因呼吸衰竭;19%已无正式镇静指征。60%的镇静患者由护士依据镇静量表滴定,Richmond躁动镇静量表使用率80%,行为疼痛量表使用率92%。常用药物为咪达唑仑(58.1%)、丙泊酚(40.5%)、舒芬太尼(67.5%);62%的镇静患者接受脑监测,颅内高压亚组升至74%。使用镇静/镇痛量表者咪达唑仑与舒芬太尼剂量更低。
要点
- 研究日246例脑损伤患者中74例(30%)镇静,其中53%因颅内高压、19%因躁动谵妄、9%因呼吸衰竭,19%已无正式镇静指征。
- 镇静患者中60%由护士依据镇静量表滴定;Richmond躁动镇静量表使用率80%,行为疼痛量表使用率92%。
- 常用镇静镇痛药为咪达唑仑(58.1%)、丙泊酚(40.5%)、舒芬太尼(67.5%);使用镇静/镇痛量表者咪达唑仑与舒芬太尼剂量更低。
- 62%的镇静患者接受脑监测,颅内高压亚组为74%,其中多模式脑监测占43.6%。
- 参与ICU可用的脑监测设备包括经颅多普勒超声(100%)、颅内与脑室内压监测(93.3%)、脑组织氧合(60%)。
适用人群与场景
- 法国30个ICU(含27个学术医院)中全部脑损伤患者,研究日共246例;其中74例(30%)接受镇静。
诊断标准与关键阈值
- 镇静深度与疼痛评估工具:Richmond躁动镇静量表用于80%的镇静患者,行为疼痛量表用于92%。
- 60%的镇静患者由护士依据镇静量表滴定镇静/镇痛药物。
处置流程与药物剂量
- 常用镇静药为咪达唑仑(58.1%)和丙泊酚(40.5%),常用阿片类为舒芬太尼(67.5%),常联合使用。
- 使用镇静/镇痛量表由护士滴定时,咪达唑仑与舒芬太尼剂量更低(原文未给出具体剂量数值)。
- 62%的镇静患者接受一种或多种脑监测设备监测;颅内高压亚组为74%,其中43.6%采用多模式脑监测。
红旗征与不能漏的情况
- 19%的镇静患者已无正式镇静指征,提示需每日评估并尽早停用不必要的镇静。
- 颅内高压患者(占镇静患者53%)镇静需平衡快速临床评估与脑顺应性受损时颅内压升高的风险。
研究设计与关键结果
- 研究类型:一日前瞻性全国观察性横断面研究,含30个法国ICU(27个学术医院)的镇静实践描述性调查及一日快照。
- 60%的镇静患者由护士依据镇静量表滴定;Richmond躁动镇静量表使用率80%,行为疼痛量表使用率92%。
- 常用药物:咪达唑仑58.1%、丙泊酚40.5%、舒芬太尼67.5%;使用镇静/镇痛量表者咪达唑仑与舒芬太尼剂量更低。
- 106例(43%)脑损伤患者使用脑监测设备;镇静患者中62%接受脑监测,颅内高压亚组为74%,多模式脑监测占43.6%。
证据类型、等级与局限
- 证据类型:前瞻性全国观察性横断面研究(非干预性),无随机对照或推荐等级。
- 局限:单日快照、样本量246例、仅为法国实践描述,不能推断因果;原文未给出具体剂量数值、效应量与置信区间。
对床旁实践的改变
- 对脑损伤镇静患者应常规使用镇静/镇痛量表(如Richmond躁动镇静量表、行为疼痛量表)由护士滴定,原文提示可降低咪达唑仑与舒芬太尼剂量。
- 每日评估镇静指征,避免无正式指征的持续镇静(原文中19%的镇静患者已无正式指征)。
- 脑损伤镇静患者应加强脑监测,尤其颅内高压患者可考虑多模式脑监测(原文中颅内高压亚组多模式监测仅43.6%)。
指南或共识出处
- SEDA-BIP-ICU研究,发表于Neurocrit Care;原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sedation/analgesia is a daily challenge faced by intensivists managing patients with brain injury (BI) in intensive care units (ICUs). The optimization of sedation in patients with BI presents particular challenges. A choice must be made between the potential benefit of a rapid clinical evaluation and the potential exacerbation of intracranial hypertension in patients with impaired cerebral compliance. In the ICU, a pragmatic approach to the use of sedation/analgesia, including the optimal titration, management of multiple drugs, and use of any type of brain monitor, is needed. Our research question was as follows: the aim of the study is to identify what is the current daily practice regarding sedation/analgesia in the management of patients with BI in the ICU in France?
METHODS: This study was composed of two parts. The first part was a descriptive survey of sedation practices and characteristics in 30 French ICUs and 27 academic hospitals specializing in care for patients with BI. This first step validates ICU participation in data collection regarding sedation-analgesia practices. The second part was a 1-day prospective cross-sectional snapshot of all characteristics and prescriptions of patients with BI.
RESULTS: On the study day, among the 246 patients with BI, 106 (43%) had a brain monitoring device and 74 patients (30%) were sedated. Thirty-nine of the sedated patients (53%) suffered from intracranial hypertension, 14 patients (19%) suffered from agitation and delirium, and 7 patients (9%) were sedated because of respiratory failure. Fourteen patients (19%) no longer had a formal indication for sedation. In 60% of the sedated patients, the sedatives were titrated by nurses based on sedation scales. The Richmond Agitation Sedation Scale was used in 80% of the patients, and the Behavioral Pain Scale was used in 92%. The common sedatives and opioids used were midazolam (58.1%), propofol (40.5%), and sufentanil (67.5%). The cerebral monitoring devices available in the participating ICUs were transcranial Doppler ultrasound (100%), intracranial and intraventricular pressure monitoring (93.3%), and brain tissue oxygenation (60%). Cerebral monitoring by one or more monitoring devices was performed in 62% of the sedated patients. This proportion increased to 74% in the subgroup of patients with intracranial hypertension, with multimodal cerebral monitoring in 43.6%. The doses of midazolam and sufentanil were lower in sedated patients managed based on a sedation/analgesia scale.
CONCLUSIONS: Midazolam and sufentanil are frequently used, often in combination, in French ICUs instead of alternative drugs. In our study, cerebral monitoring was performed in more than 60% of the sedated patients, although that proportion is still insufficient. Future efforts should stress the use of multiple monitoring modes and adherence to the indications for sedation to improve care of patients with BI. Our study suggests that the use of sedation and analgesia scales by nurses involved in the management of patients with BI could decrease the dosages of midazolam and sufentanil administered. Updated guidelines are needed for the management of sedation/analgesia in patients with BI.
参考来源
- Poignant S, Vigué B, Balram P, et al. A One-Day Prospective National Observational Study on Sedation-Analgesia of Patients with Brain Injury in French Intensive Care Units: The SEDA-BIP-ICU (Sedation-Analgesia in Brain Injury Patient in ICU) Study. Neurocrit Care. 2021. PMID: 34331208. doi:10.1007/s12028-021-01298-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。